Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04', 'hotel', 'friends'] | 6/5/2022 18:43 | 1,530,000,000,000,000,000 | and the day at #asco22 is over. great presentations (i.e. destiny-breast04) and so many chats with friends and colleagues. time to head back to the hotel ..bye mccormick. see u tomorrow | Medical Oncologist, department of oncology at the University hospital of Geneva (HUG). All opinions expressed here are my own | Individual | HCP |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'thanks', 'breast', 'enhertu'] | 6/5/2022 19:00 | 1,530,000,000,000,000,000 | sunday #asco2022 highlights from our s+r team...quick strategy session thanks to #boehringeringelheim, indulging in sweet treats and a standing ovation for the phase lll destiny-04 her2 low abstract presentation! huge news for metastatic breast cancer patients! #enhertu | Research + Strategy = Insights + Ideas. Helping clients find new pathways to grow since 1955 | Company / Organization | Consulting / Analytics |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'destiny-breast04'] | 6/5/2022 19:00 | 1,530,000,000,000,000,000 | this right here is my favorite moment of #asco22. standing ovation for the practice changing destiny-breast04:tdxd in low her2 mbc. | HematologyOncology Chief Fellow at Stephenson Cancer Center University of Oklahoma #OU @ouhealth Former HPM fellow #pallonc Music food and travel enthusiast | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destinybreast04'] | 6/5/2022 19:02 | 1,530,000,000,000,000,000 | and the high incidence of nausea was before routine antiemetics were prescribed, right? #asco22 #destinybreast04 #bcsm | (former) doctor, mother, woman LIVING with metastatic breast cancer. Grant reviewer. Conference goer. METAvivor board member. She/her. #NotDeadYet for 8 years | Individual | Advocacy / Charity |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | gi,other | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'breast', 'enhertu'] | 6/5/2022 19:35 | 1,530,000,000,000,000,000 | sorry to be missing the buzz of asco and the amazing data (mmr- crc w/ i/o! enhertu destiny breast4! target-rich cholangiocarcinoma!). gotta trade asco for #agbt2022 let s do this again! | Sequencing, genomics, companion diagnostics, biotech, and chortles. Tweets are my own. Eat more donuts, do more squats ?? ??????? | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 20:04 | 1,530,000,000,000,000,000 | impressive promising results! #destinybreast04 #asco22 | ?? Assistant Professor - Seidman Cancer Center @UHospitals | Case Western Reserve University @CWRU ?? #ASCO22 ? | Bot / Aggregator | Media / News |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 20:17 | 1,530,000,000,000,000,000 | updated: #asco22: enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way - endpoints news | Show her breasts on the web is right, show them to the doctor is better! photo : boobstagramm@gmail.com | Bot / Aggregator | Blogger / Random / Other |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['biomarker', 'trastuzumab', 'breast'] | 6/5/2022 20:30 | 1,530,000,000,000,000,000 | destiny trial results are profound. but why? high false negatives of her2 ihc? false thinking about binary biomarkers? off target effect of the agent? trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | #asco22 | Prostate cancer medical oncologist and physician-scientist, Kendrick Family Chair for Prostate Cancer Research, Cleveland Clinic. Posts are my own. | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 21:03 | 1,530,000,000,000,000,000 | enhertu already delivered several outstanding results in her2-positive breast cancer and now shown an impressive survival benefit over chemotherapy in patients considered her2-negative, with the data holding up even in those with the very lowest expression | null | Bot / Aggregator | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 21:30 | 1,530,000,000,000,000,000 | after a full day of studying for im boards, i m finally able to get back to my on demand content at #asco22 ! first stop, destiny-breast04 randomized phase 3 trial! promising news to the future of #breastcancertreatment | Internal Medicine Resident Physician at Southeast Health. Proud ????. Future Oncologist ???? | Individual | HCP |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 21:40 | 1,530,000,000,000,000,000 | a game-changer in breast cancer and a major win for antibody-drug conjugate class of drugs. her2-targeting trastuzumab deruxtecan better than chemotherapy in previously treated her2-low(!) advanced breast cancer #asco22 | Director, Englander Institute for Precision Medicine @WCMenglanderIPM, Associate Director @wcmc_ctsc & ICB, Co-Founder @volastratx & @onethreebiotech | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'destiny04', 'congrat', 'thank you', 'breast', 'astrazeneca'] | 6/5/2022 21:52 | 1,530,000,000,000,000,000 | a landmark day at #asco2022; we are so excited by the #destiny04 data and what it means for the breast cancer community. this is an opportunity to transform the soc in her2-low #mbc both hr + and -. congratulations & thank you to dr. modi, astrazeneca and daiichi sankyo. | Improving patient outcomes with AI-powered pathology. | Company / Organization | Media / News |
Not Tagged | Not Tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'astrazeneca'] | 6/5/2022 22:12 | 1,530,000,000,000,000,000 | 'dramatic' study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer via | null | Individual | Blogger / Random / Other |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'pearl', 'breast'] | 6/5/2022 22:33 | 1,530,000,000,000,000,000 | some impressive oncology pearls 12-months after hem/onc fellowship grad, i found out that breast ca understanding has changed: her2 1+ or 2+ ish-neg are not necessarily her2-neg but her2-low longer pfs & os with trastuzumab deruxtecan. what a practice changing trial!#asco22 | BMT fellow #Tx & #CARTcells @MayoClinic | Previous Hematology-Oncology Fellow @AUB_Lebanon | EBMT Young Ambassador 2018 | My tweets are my own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 22:48 | 1,530,000,000,000,000,000 | with a wife that passed of #metatstaticbreastcancer, results like destiny-breast04 mean so much. as both a #patientadvocate and a technology exec from early days of apple to many a startup, constantly thinking how do get all this to the right patients at the right time? #asco22 | GM, Community & Experiences, Executive Council | TEDx Speaker | Chair, Side-Out Foundation | Maureen, my love, passed 10.21.2014 of #breastcancer #SheisMyWhy | Individual | Blogger / Random / Other |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 22:57 | 1,530,000,000,000,000,000 | fam-trastuzumab deruxtecan-nxki doubles progression-free survival in her2-low metastatic breast cancer - the asco post | null | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 23:22 | 1,530,000,000,000,000,000 | destiny-breast04 - found this in the protocol pts have to have exactly one or two prior lines of tx but prior cdk4/6 doesn't count? #asco22 | Oncology Pharmacist - Inspired by VP's Plenary Session
war on drugs = war on the FDA | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'destiny-breast04'] | 6/5/2022 23:40 | 1,530,000,000,000,000,000 | destiny-breast04 - trastuzumab deruxtecan 100 mg per vial $2,909.40 @ 5.4 mg/kg *75kg = 405 mg, 5 vials (if you dont round) = $14,547 per treatment. and how many pts are her2-low?! +12% ild, how much will ild management cost?
#asco22 #asco | Oncology Pharmacist - Inspired by VP's Plenary Session
war on drugs = war on the FDA | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 0:48 | 1,530,000,000,000,000,000 | asco: astrazeneca, daiichi's enhertu could transform breast cancer treatment with landmark her2-low show | Plenty of #news from the world of #business and #finance.
We make #Crypto and #NFTs Advertising.
Service provided by #PubliAdmedia | Company / Organization | Media / News |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['paradigm', 'breast', 'enhertu', 'astrazeneca'] | 6/6/2022 2:02 | 1,530,000,000,000,000,000 | asco: astrazeneca's enhertu is poised to change the breast cancer paradigm #pharmascrip | Scrip goes beyond the headlines to deliver insight & analysis on drug discovery, development and product life cycle value chain.
Join us, find our latest job: | Company / Organization | Healthcare |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'trastuzumab'] | 6/6/2022 2:19 | 1,530,000,000,000,000,000 | much awaited presentation at #asco2022. fam-trastuzumab deruxtecan-nxki doubles progression-free survival in her2-low metastatic breast cancer - the asco post | Oncologist, researcher and educator, cancer centre head at @PantaiHospKL, cancer doc at Subang Jaya Medical Centre, Secretary @ Malaysian Oncology Society | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 3:34 | 1,530,000,000,000,000,000 | (updated: #asco22: enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way endpoints news) has been published on the globe - | null | Unknown / Deleted | Unknown / Deleted |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 4:04 | 1,530,000,000,000,000,000 | #asco : #astrazeneca, daiichi's enhertu could transform breast cancer [ ] her2 expression is determined by two tests, one called an immunohistochemical 'the top line' podcast : covid therapies dominate 2021's top-selling drugs | Journaliste Français indépendant installé en Suisse, Observateur spécialisé en analyse de reportages et de témoignages internationaux diffusé sur le web | Company / Organization | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'astrazeneca', 'daiichi'] | 6/6/2022 4:50 | 1,530,000,000,000,000,000 | destiny breast-04 data reveal at #asco22 is a big win for and in her2-low breast cancer that according to some experts could change treatment practice #oncology | https://t.co/O0ZJQGMjEP, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate | Company / Organization | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast'] | 6/6/2022 5:40 | 1,530,000,000,000,000,000 | #asco22 we are all encouraged to see the results announced of the destiny-breast 04 study. advocates work and look forward to the day when there is a definitive end to #breastcancer #nationalcancersurvivorsday | Co-Operations Mgr. RVA Career ExpoSpring 2018 #ProjectManagement #Consulting #VendorManagement #TrainingandDevelopment | Individual | Blogger / Random / Other |
KCSG-HB19-14 | trastuzumab | astrazeneca,daiichi sankyo | not tagged | 1 | ['trastuzumab', 'thanks'] | 6/6/2022 5:50 | 1,530,000,000,000,000,000 | my poster presentation @ #asco2022. phase ii trial of trastuzumab plus folfox for #her2 positive #biliarytractcancer. thanks to my collaborators at #kcsg (korean cancer study group). | Medical Oncologist. Yonsei Cancer Center. #gicancers #pancreaticcancer #biliarytractcancer #gastriccancer #hcc | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | not tagged | 1 | ['beat', 'enhertu', 'astrazeneca', 'daiichisankyous', 'daiichi'] | 6/6/2022 5:58 | 1,530,000,000,000,000,000 | #esmo 2016 in #copenhagen had 1 lonely poster on phase 1 #enhertu. in 2022 #asco plenary standing ovation! like #thebeatles journey from #hamburg to shea stadium. | Cancer specialist searching the world for better therapy | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04'] | 6/6/2022 6:09 | 1,530,000,000,000,000,000 | 1. access to journals & therefore knowledge can be inequitable given lack of universal open access. in the spirit of this years asco of advancing equitable cancer care through innovation i m tweeting the figures of the landmark destiny-breast04 study. #asco2022 | Professor of Translational Oncology and Consultant Medical Oncologist | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'trastuzumab', 'astrazeneca'] | 6/6/2022 6:19 | 1,530,000,000,000,000,000 | when i joind astrazeneca, a destiny breast study with trastuzumab-deruxtecan was the first study handed to me. watching the reaction of the oncology community to destiny breast 04 data at #asco22 is just humbling! a great day in the fight against breast cancer. very proud | Cancer Scientist | In May 22 I quit my job at BigPharma to build @itsYendou and accelerate the race to cancer cure. Here I tweet about my journey | Individual | Research / Science |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'destiny,breast,4', 'breast', 'enhertu', '$dsnky', '$azn'] | 6/6/2022 6:21 | 1,530,000,000,000,000,000 | both $azn and $dsnky have products and development projects beyond enhertu, but today's price action revolves around yesterday's asco destiny breast04 news and the expected impact or non-impact of it. | I value data, science & intelligent contributions (content+context).
If you don't, don't follow me & don't reply 2 my tweets.
Disclaimer: Not investment advice. | Individual | Consulting / Analytics |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['friends', 'breast', 'enhertu', 'astrazeneca'] | 6/6/2022 6:47 | 1,530,000,000,000,000,000 | #asco22: when camille hertzka found out the results of a study showing breast cancer drug enhertu cut disease progression or death by about half, the astrazeneca vp immediately thought of the potential for patients, some of whom are friends. | The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs | Bot / Aggregator | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04'] | 6/6/2022 7:31 | 1,530,000,000,000,000,000 | destiny-breast04: trastuzumab deruxtecan resulted in significantly longer pfs and os than the physician s choice of chemotherapy in pts with her-2 low metastatic breast cancer #asco22 | Assistant Prof | Thoracic Oncology & Phase-I @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['paradigm', 'breast', 'enhertu'] | 6/6/2022 7:37 | 1,530,000,000,000,000,000 | enhertu benefit in her2-low breast cancer wows at #asco22; signals shifting therapy, dx paradigms | Journalist: Personalized medicine, genomics, cancer; Managing editor: @PrecOncNews
https://t.co/t2jQRuYQgf
@GenomeWeb
https://t.co/MOrpOLPAKt | Individual | Media / News |
not tagged | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'trastuzumab'] | 6/6/2022 7:41 | 1,530,000,000,000,000,000 | standing ovation at #asco2022. plenary session. trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm | I am a medical oncologist and the Principal Investigator of the American Society of Clinical Oncology TAPUR study. Tweets are my own. | Individual | Professional |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['paradigm', 'breast', 'enhertu'] | 6/6/2022 7:59 | 1,530,000,000,000,000,000 | enhertu benefit in her2-low breast cancer wows at asco; signals shifting therapy, dx paradigms. oncologists at asco cheered data showing the drug significantly cut the risk of disease progression or death, but experts wondered how existing her2... | null | Bot / Aggregator | Media / News |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', '$dsnky', '$azn'] | 6/6/2022 8:04 | 1,530,000,000,000,000,000 | $azn $dsnky updated: #asco22: enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way - | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 8:35 | 1,530,000,000,000,000,000 | #asco22 astrazeneca, daiichi s enhertu could transform breast cancer treatment with landmark her2-low show | Sales Director in #LifeSciences #CDx #Genomics. Dad to Freddie & Phoebe, football (well, goal hanger), runner & all round good egg! | Individual | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast', 'breakfast'] | 6/6/2022 8:42 | 1,530,000,000,000,000,000 | breakfast with dr modi. #destinybreast04 in perspective. #asco22 | Interested in #Breastcancer #Cancerreseach. | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 9:04 | 1,530,000,000,000,000,000 | asco22: enhertu aces key her2-low test in breast cancer | The original site for employees in pharma, medical, and diagnostic sales and related industries. Join us and stay informed. | Company / Organization | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04', 'mbc'] | 6/6/2022 9:20 | 1,530,000,000,000,000,000 | not that many presentations get standing o's at asco this one did her2-low unresectable and/or metastatic breast cancer (mbc): results of destiny-breast04, a randomized, phase 3 study | Sixty percent of the time, the things I try work every time. Radiation oncologist. Thaumaturgist. Todd Scarbrough is an anagram for 'doc brought rads.' | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 9:28 | 1,530,000,000,000,000,000 | the enhertu data presented at asco received a standing ovation for its ability to halt disease progression and extend overall survival for her-2 low breast cancer patients. we cannot cure cancer yet, but the hope of it glimmers on the horizon. | SVP, Strategic Development at EVERSANA Intouch, Founder at Seamripper, Adjunct Faculty @TCU, aspiring theologian @PerkinsSMU Alum: @TAMU @SCADdotedu | Individual | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast'] | 6/6/2022 9:43 | 1,530,000,000,000,000,000 | yesterday at the plenary session regarding #destinybreast04 made history in medical oncology arena. happy to share this moment in vivo. | Pasando por la vida con alegría. Resiliente. Opinions are my own?????? | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 10:07 | 1,530,000,000,000,000,000 | asco22: enhertu aces key her2-low test in breast cancer | Healthcare Industry Commercial Advisor | Analytics Driven Business Insights | Cyclist | Individual | Consulting / Analytics |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast'] | 6/6/2022 10:31 | 1,530,000,000,000,000,000 | while the west is rejoicing with the results of destiny breast 04 trial & the plenary session at #asco22, i am wondering if it will go beyond theoretical knowledge in this part of the world.. "close the care gap" is such a reality | Additional Professor of Surgery (breast-endo surgery as surgical forte), AIIMS New Delhi. Tweets in personal capacity, RT# endorsement, Nation first | Individual | HCP |
DESTINY-Breast04 | trastuzumab | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'trastuzumab'] | 6/6/2022 10:36 | 1,530,000,000,000,000,000 | the hits just keep coming for trastuzumab - 20+ years after 1st approval of the her2 targeting antibody, incredible results in a new breast cancer population. | Transformation & transcendence through biotechnology. https://t.co/gI5AiWSqUm @lab_dao | Individual | Pharma / Biotech |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-04'] | 6/6/2022 11:10 | 1,530,000,000,000,000,000 | destiny-04 data will change #breastcancer care today. listen to and discuss the data and what it means for patients. #asco22 | Oncology and HCP editorial lead @RemHealthMedia, OBRoncology and @PatientPower. Science and medical writer, former bench scientist. Tweets are my own. She/her | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'destiny-04'] | 6/6/2022 11:23 | 1,530,000,000,000,000,000 | it s here!!! it s here!!! check out this landmark interview between and about the destiny-04 trial! #bcsm #obroncology #asco22 | Executive Managing Editor of #OBROncology (https://t.co/XW1VL90pYg) and #PatientPower (https://t.co/WHsQe8gmv5) at Remedy Health Media. Opinions are mine. | Individual | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'destiny,breast,4', 'breast', 'destiny-breast04'] | 6/6/2022 11:34 | 1,530,000,000,000,000,000 | as a #communityoncology md - i go home thinking of a new category of #breastcancer her2 low #destiny-breast04 #bcsm | ASCO, ASH, EHA & ESMO Member - fr FT academic, traveller, foodie & now private practice! #girldad #boydad #hematology #oncology | Individual | HCP |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'trastuzumab'] | 6/6/2022 11:38 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan cuts risk of disease progression or death by 50% for patients with her2-low metastatic breast cancer. #asco22 | The American Journal of #ManagedCare is a peer-reviewed, indexed publication. https://t.co/I2WRhmhOVC offers news in health policy, disease states, and managed care. | Company / Organization | Publication / Journal |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04', 'enhertu'] | 6/6/2022 12:06 | 1,530,000,000,000,000,000 | results of the destiny-breast04 were presented at #asco22 yesterday showing that enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with her2-low metastatic breast cancer with hr-positive and hr-negative disease. | We are a boutique management consulting firm that partners with biotech, IVD, and life science clients globally to develop insight-driven business solutions. | Company / Organization | Consulting / Analytics |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 12:42 | 1,530,000,000,000,000,000 | updated: #asco22: enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way endpoints news | MS,MBA: Performance-driven professional, with a passion for Medicine, Biotechnology, Finance, Service Oriented Leadership and Entrepreneurship. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04'] | 6/6/2022 13:56 | 1,530,000,000,000,000,000 | #asco22 highlights:
1.spent time w/ my future co-fellows
2.connected and watched present after knowing her for many years
3.being in the room when dr. modi received a standing ovation for destiny-breast04. i had goosebumps. can t wait to start fellowship soon! | Chief resident @loyolaIMRES | future @LoyolaOnc fellow. Love Peloton, Thai food, thriller/mystery mini-series, Spanish music, OrangeTheory, MedEd (no order) | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'destiny,breast,4', 'breast', 'destiny-breast04'] | 6/6/2022 14:01 | 1,530,000,000,000,000,000 | breaking #asco22 news: novel anti-body drug conjugate doubles progression-free survival in her2-low metastatic breast cancer. dr. modi breaks down some of the findings in the destiny-breast04 trial. #bcsm | Scientist with 25 yrs' experience in Pharmaceutical R&D and Medical Communications. | Individual | Research / Science |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 14:04 | 1,530,000,000,000,000,000 | asco: astrazeneca, daiichi s enhertu could transform breast cancer treatment with landmark her2-low show | Access to First Databank's drug pricing database with more than 90 attributes & data points for virtually every FDA approved drug. #DrugPricing
RT?Endorsement | Company / Organization | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast'] | 6/6/2022 14:17 | 1,530,000,000,000,000,000 | it's amazing how twitter made me feel part of #asco22 although i was not able to be there. really excited about many presentations but mostly for #destinybreast04 . game changing. | Internal Medicine Resident.
Interested in Heme/Onc
Living in Boston.
Classical violinist.
Ecuadorian | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast', 'trastuzumab'] | 6/6/2022 15:00 | 1,530,000,000,000,000,000 | #trastuzumabderuxtecan ushers in new treatment era for #her2lowbreastcancer #destinybreast04 extends agent's benefits to historically tough-to-treat disease
shanu modi, md | Associate Professor Radiology in Breast Imaging | Alum @MayoClinicSOM @HarvardChanSPH | #BreastCancer #AI #PublicHealth | Tweets?Endorsement | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['biomarker', 'destiny04'] | 6/6/2022 15:03 | 1,530,000,000,000,000,000 | the new her2 testing discussion among pathologists after #destiny04 trial #asco22 pointing out both the limits of ihc, as well as the promise for pts that we don't have a true biomarker right now to at least most be able to access t-dxd... | Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine. | Individual | HCP |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'daiichi'] | 6/6/2022 15:04 | 1,530,000,000,000,000,000 | oncologists can celebrate like football fans too! showing data from a breakthrough breast cancer drug enhertu, developed by and at #asco22. patients on enhertu lived 7 months longer than on standard chemo. | @RyvuTx CEO, @SelvitaKrakow and @Ardigen_SA co-founder, ex. @Comarch and https://t.co/HuuMtVdzI9. Private opinions. | Individual | Pharma / Biotech |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04'] | 6/6/2022 15:48 | 1,530,000,000,000,000,000 | destiny-breast04 phase iii trial showed trastuzumab deruxtecan improved both pfs and os in her2-low unresectable and/or metastatic breast cancer regardless of hormone receptor (hr) status versus physician s choice of chemotherapy. #asco22 | Chief MedOnc @SylvesterCancer. Helping improve Cancer Control in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | gi | 1 | ['enhertu', 'rectal'] | 6/6/2022 17:49 | 1,530,000,000,000,000,000 | was planning to cover #asco2022 in detail - but..... is it me or not much to talk about? seems as if enhertu and the rectal cancer story are the only meaningful updates......am i missing something? | Weekly Biotech Market Updates, Career Advice & Consulting | ?? Instagram: @bowtiedbiotech | ?? web: https://t.co/ayyMxLo0M9 | ?????? | Company / Organization | Pharma / Biotech |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['enhertu'] | 6/6/2022 18:00 | 1,530,000,000,000,000,000 | swing low, sweet enhertu: , daiichi data carry her2 message home #biotech #pharma #asco22 | Biopharma’s trusted news source. Lynn Yoffee, Jennifer Boggs, Anette Breindl, Michael Fitzhugh, Lee Landenberger, Randy Osborne, Mari Serebrov, Richard Staines | Company / Organization | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['in person', 'destiny,breast,4', 'breast', 'destiny-04'] | 6/6/2022 18:20 | 1,530,000,000,000,000,000 | as an aspiring oncologist, it is incredible to see the results of destiny-04 and the changes in the treatment of advanced breast cancer. hoping to attend #asco next year in person! | Medical Student at @UNIRIO_Oficial ???? | English, Portuguese, French | Aspiring Oncologist ???? | Interested in breast and gynecologic cancers | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04'] | 6/6/2022 20:00 | 1,530,000,000,000,000,000 | the phase 3 destiny-breast04 trial using fam-trastuzumab deruxtecan-nxki showed a reduction in the risk of disease recurrence or death for patients with her2-low, hormone receptor positive metastatic breast cancer. #bcsm #asco22 | | Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more. | Company / Organization | Publication / Journal |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/6/2022 22:28 | 1,530,000,000,000,000,000 | asco: enhertu to transform breast cancer with her2-low show | PhD of Pharm-Science. Visiting scholar at department of bioengineering. Nanomedicine and biomaterials | Individual | Research / Science |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/7/2022 22:28 | 1,530,000,000,000,000,000 | #breastcancer drug trial results in unheard-of survival rates. for some patients with metastatic tumors not significantly affected by other forms of chemotherapy, the treatment, #enhertu, halted their cancer s growth, by via #asco22 | André Picard is the health columnist at The Globe and Mail. Author of the bestselling book "NEGLECTED NO MORE". | Individual | Publication / Journal |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'bcsm'] | 6/7/2022 21:29 | 1,530,000,000,000,000,000 | glad to see this got media coverage! fantastic article in by - here s the video of the standing ovation! #breastcancer #bcsm #asco22 #enhertu | Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ?? | Individual | HCP |
not tagged | not tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'daiichisankyous', 'astrazeneca', 'daiichi', 'astrazenecaus'] | 6/7/2022 20:27 | 1,530,000,000,000,000,000 | 'dramatic' study results for , drug suggest new way to treat aggressive #breastcancer | #her2expression #bioinformatics #asco22 | Advancing Precision Medicine @TempusLabs || #MedTwitterAI #RealWorldEvidence || Own Views | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny 04'] | 6/7/2022 19:42 | 1,530,000,000,000,000,000 | i excellent summary of the findings of destiny 04 by #asco22 quoting one of our patients from and | Prof. & Chair Dept. of Heme and Oncology @ClevelandClinic @NRGonc Deputy Editor @JCOOP_ASCO Tweets are mine. No act of #Kindness is ever wasted #CleClinicCancer | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast'] | 6/7/2022 19:06 | 1,530,000,000,000,000,000 | i fell out of my chair when i saw vp mention me in the latest ! i never thought this would happen. i learned almost everything i know about interpreting trials from ! must watch on destiny-breast 04 #asco #asco22 | Oncology Pharmacist - Inspired by VP's Plenary Session
war on drugs = war on the FDA
Kaiser Permanente | Individual | HCP |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'bcsm'] | 6/7/2022 18:53 | 1,530,000,000,000,000,000 | this is about more than just this drug or even breast cancer. its real advantage is that it enables us to take potent therapies directly to cancer cells. commenting on the impact of #enhertu #asco22 #bcsm | Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer. | Company / Organization | Hospital / Clinic |
not tagged | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/7/2022 16:00 | 1,530,000,000,000,000,000 | an researcher noted that enhertu should become the standard of care for her2-low, hr+ metastatic breast cancer after findings presented at #asco22 showed that the drug significantly improved survival. | Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey. | Company / Organization | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'mbc', 'destiny-breast04'] | 6/7/2022 11:40 | 1,530,000,000,000,000,000 | #asco22 | tells us about the #standingovation for the amazing results of the destiny-breast04 trial: a statistically significant and clinically meaningful benefit in pfs and os compared to standard-of-care treatment in pts with her2-low #mbc. | Latest research in oncology | Breaking news, insights, interviews, live tweeting and updates from major conferences | Published by @ilpensiero | @think2it | Company / Organization | Media / News |
not tagged | not tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'astrazeneca', 'daiichi'] | 6/7/2022 11:01 | 1,530,000,000,000,000,000 | #cc4oc 'dramatic' study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer via | null | Individual | Blogger / Random / Other |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'destiny-breast04'] | 6/7/2022 10:42 | 1,530,000,000,000,000,000 | tsg reports live from chicago #asco22: the ground-breaking destiny-breast04 trial received a standing ovation. here s what we thought about the presentation! #tsgcongresscoverage | Dedicated to scientific strategy that creates epiphany moments with healthcare audiences | Company / Organization | Consulting / Analytics |
not tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/7/2022 9:44 | 1,530,000,000,000,000,000 | was quoted in a article discussing the #tdxd (enhertu) drug. new data presented at #asco22 are from #breastcancers that have low levels of her2, meaning that a wider range of pts might benefit from the drug. | Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425 | Company / Organization | Hospital / Clinic |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast'] | 6/7/2022 9:22 | 1,530,000,000,000,000,000 | my video for destiny breast 04 is up
if you have to present an asco abstract at your institution, i hope these videos help you this wasn't an easy trial to deconstruct | Medicine Oncology Science Policy
Academic Pubs @vkprasadlab
Podcast @plenary_session
Clips on YouTube ??
Books EMR & Malignant
Prof @ucsf_epibiostat
Views mine | Individual | HCP |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'bcsm', '$azn', 'astrazeneca', 'daiichi'] | 6/7/2022 9:08 | 1,530,000,000,000,000,000 | astrazeneca, daiichi s enhertu could transform breast cancer treatment with landmark her2-low show. how will enhertu change #breastcancer treatment for patients previously categorized as her2-negative? #asco22 #bcsm $azn | Actionable Strategies for Life Sciences | Company / Organization | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'bcsm', 'destiny-breast04'] | 6/7/2022 9:03 | 1,530,000,000,000,000,000 | breaking #asco22 news: novel anti-body drug conjugate doubles progression-free survival in her2-low metastatic breast cancer. dr. modi breaks down some of the findings in the destiny-breast04 trial. #bcsm | Leadership and learning are indispensable to each other. John F. Kennedy | Individual | Consulting / Analytics |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'astrazeneca'] | 6/7/2022 7:10 | 1,530,000,000,000,000,000 | hugely promising results from the enhertu trial by great news for patients with breast cancer that gets picked up at later stages #cancer #genomics #asco22 screenshot below, full article at: (link should hopefully go thru paywall) | CEO at @GenomicsEngland; husband and father of 3. Formerly COO at @quantumblack, Partner @mckinsey, UK diplomat, @bbc. Views are personal. | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'destiny-04', 'breast', 'bcsm'] | 6/7/2022 6:59 | 1,530,000,000,000,000,000 | listen in as , executive vice president of , and , vice president for clinical research at , discuss what the results of destiny-04 mean for breast cancer care. #bcsm #asco22 | OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals. | Company / Organization | Media / News |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/7/2022 5:38 | 1,530,000,000,000,000,000 | asco: enhertu to transform breast cancer with her2-low show | Biotech/healthcare investor. Father to 3 great girls | Individual | Finance / Investment |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'bcsm', 'destiny-breast04'] | 6/7/2022 5:37 | 1,530,000,000,000,000,000 | breaking #asco22 news: novel anti-body drug conjugate doubles progression-free survival in her2-low metastatic breast cancer. dr. modi breaks down some of the findings in the destiny-breast04 trial. #bcsm | True Marketeer, works at Parexel, one who literally lives to eat(ing) and read(ing) in that order &..& (Self-proclaimed) arbiter of taste. guess | Individual | Consulting / Analytics |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/7/2022 5:21 | 1,530,000,000,000,000,000 | enhertu could transform #breastcancer treatment, landmark her2-low trial suggests. #asco22 | Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME. | Company / Organization | Media / News |
not tagged | not tagged | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'astrazeneca', 'daiichi'] | 6/7/2022 5:20 | 1,530,000,000,000,000,000 | 'dramatic' study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer > | An entrepreneur, now mentor, and growth stage investor discusses venture capital, startups, entrepreneurism, emerging tech and barriers to success along the way | Individual | Finance / Investment |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/7/2022 5:17 | 1,530,000,000,000,000,000 | updated: #asco22: enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way - endpoints news | Show her breasts on the web is right, show them to the doctor is better! photo : boobstagramm@gmail.com | Bot / Aggregator | Blogger / Random / Other |
not tagged | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'bcsm'] | 6/7/2022 2:07 | 1,530,000,000,000,000,000 | medscape: enhertu could transform #breastcancer treatment, landmark her2-low trial suggests. #asco22 #bcsm | Make life a little bit more cheerful is my main goal. I love to laugh, make people happy, and share interesting articles about health. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,allist | other | 1 | ['destiny,breast,4', 'breast', 'bcsm', 'destiny-breast04', 'allist'] | 6/7/2022 4:35 | 1,530,000,000,000,000,000 | breaking #asco22 news: novel anti-body drug conjugate doubles progression-free survival in her2-low metastatic breast cancer. dr. modi breaks down some of the findings in the destiny-breast04 trial. #bcsm | PhD CMPP, ex-geneticist/neuroscientist with a love of SpaceX and Formula 1. #Medcomms #Scicomms #parexel | Individual | Research / Science |
not tagged | not tagged | astrazeneca,daiichi sankyo,anzup | other | 1 | ['breast', 'evolution', 'enhertu', 'fierce'] | 6/6/2022 10:54 | 1,530,000,000,000,000,000 | enhertu's historic her2-low breast cancer data also sparked talks of the need for a her2 diagnostic revolution. #asco22 | Tweets from the Fierce Life Sciences editorial team | Company / Organization | Media / News |
not tagged | not tagged | astrazeneca,daiichi sankyo,anzup | other | 1 | ['breast', 'evolution', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 10:22 | 1,530,000,000,000,000,000 | asco: her2 diagnostics need a revolution as astrazeneca, daiichi s enhertu looks to redefine breast cancer more medical news at #epidemiology #medtwitter #meded #mednews | #Epidemiology news from major publishers consolidated for a more streamlined industry news experience.?????? | Company / Organization | Media / News |
not tagged | not tagged | astrazeneca,daiichi sankyo,anzup | other | 1 | ['breast', 'evolution', 'enhertu', 'astrazeneca', 'daiichi'] | 6/6/2022 10:15 | 1,530,000,000,000,000,000 | asco: her2 diagnostics need a revolution as astrazeneca, daiichi s enhertu looks to redefine breast cancer | Medical device and digital health consulting firm focused on product development, quality, and regulatory compliance for US, EU, South America, and Asia. | Company / Organization | Consulting / Analytics |
not tagged | not tagged | astrazeneca,daiichi sankyo,anzup | other | 1 | ['breast', 'evolution', 'enhertu', 'astrazeneca', '$dsnky', '$azn', 'daiichi'] | 6/6/2022 12:41 | 1,530,000,000,000,000,000 | $azn $dsnky asco: her2 diagnostics need a revolution as astrazeneca, daiichi s enhertu looks to redefine breast cancer | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
destiny-breast04 | ,,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'enhertu', 'destiny-breast04', '$azn', '$dsnky'] | 6/7/2022 5:46 | 1,530,000,000,000,000,000 | what's the trading strategy for $infi after #enhertu data in her2 low and destiny-breast04 presentation at #asco22 plenary session. $azn $dsnky | Ideas. Not advice.
I trade on market sentiments combined with deep value and stock analysis.
Momentum stocks. Long only. Often contrarian.
Looking for Alpha | Individual | Finance / Investment |
destiny-breast04 | ,,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'enhertu', 'destiny-breast04', 'astrazeneca'] | 6/7/2022 0:26 | 1,530,000,000,000,000,000 | updates: has presented the potentially practice-changing results of the destiny-breast04 trial of #enhertu in her2-low metastatic breast cancer vs. treatment of physician s choice. learn more: | #DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry | Company / Organization | Consulting / Analytics |
destiny-breast04 | ,sacituzumab govitecan,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,gilead sciences | other | 1 | ['breast', 'trodelvy', 'destiny-breast04', '$gild'] | 6/5/2022 17:20 | 1,450,000,000,000,000,000 | w fargo: $gild trodelvy's fate in hr+ breast may meet its destiny-breast04 #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Dramatic | Not Tagged | astrazeneca,daiichi sankyo,gilead sciences,roche,seagen | other | 1 | ['breast', '$rhhby', '$sgen', '$azn', '$gild', '$dsnky', 'astrazeneca'] | 6/5/2022 7:07 | 1,530,000,000,000,000,000 | new: dramatic' study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer $azn $dsnky $rhhby $sgen $gild #asco22 | Biotech Journalist; Senior Editor, BioPharma Dive | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,jw therapeutics | other | 1 | ['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04', 'jw'] | 6/6/2022 18:30 | 1,530,000,000,000,000,000 | christine sadlowski talks with dr. shanu modi about the destiny-breast04 study, which looked at trastuzumab deruxtecan for advanced her2-low breast cancer. #asco22 #breastcancer | Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news. | Bot / Aggregator | Publication / Journal |
destiny-breast04 | ,bevacizumab,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,roche | gi,other | 1 | ['#gi', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'breast', 'destinybreast04', 'gi '] | 6/5/2022 16:45 | 1,530,000,000,000,000,000 | live footage of #gi oncologists applauding at the #asco22 plenary for the 6 months os gain in #destinybreast04 after yet another trial comparing first line doublet + egfri or bev in #mcrc with minimal differences between arms | MD - GI oncology @uzleuven @KU_Leuven | Individual | HCP |
Not Tagged | ,glofitamab,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,roche | melanoma | 1 | ['melanoma', 'enhertu'] | 6/6/2022 10:03 | 1,530,000,000,000,000,000 | asco was good demonstration of high quality science from small cap biotechs, with groundbreaking data on large oncology populations such as metastatic uveal melanoma and nrg1 fusion tumors. mid-large caps work on fraudulent drugs like glofit/enhertu | Official ?? (???) fan account. Online content creator, exclusively @onlyfans She/Her/Hers. | Individual | Finance / Investment |
destiny-breast04,determination,paradigm,reecur | dexamethasone,,lenalidomide,bortezomib,Panitumumab,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,takeda,amgen | multiple myeloma,gi,other | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bcsm', 'crcsm', 'scmsm', 'determination', 'destiny-breast04', 'sarcoma', 'breast', 'mmsm'] | 6/4/2022 22:00 | 1,530,000,000,000,000,000 | stay tuned for our update from #asco22.
our experts share their view on the impact of today's lba plenary: - - paradigm in #crcsm
- - reecur in ewing sarcoma #scmsm
- - destiny-breast04 in #bcsm
- prof lee - determination in #mmsm #meded | COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally. #COR2ED #MedEd #IME | Company / Organization | Healthcare |
echelon1 | ,brentuximab vedotin,trastuzumab deruxtecan | astrazeneca,daiichi sankyo,takeda,seagen | lymphoma | 1 | ['echelon-1', 'enhertu', 'takeda', 'seagen'] | 6/4/2022 16:13 | 1,530,000,000,000,000,000 | takeda / seagen os data in hl - echelon-1 is pretty impressive too. plenary tomorrow abstract 3: enhertu should be the highlight of #asco22 | venture capital / waves / biotech / coffee / pharma | Individual | Pharma / Biotech |